Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88824 | 0.93 | REN (0.37) | HTR1ASLC6A4PARP1PTGS2REN | |
| SCHEMBL10283463 | 0.88 | SLC6A4 (0.41) | HTR1ASLC6A4PARP1RENCYP2D6 | |
| SCHEMBL89476 | 0.88 | SLC6A4 (0.43) | HTR1ASLC6A4PARP1CYP2D6CXCR3 | |
| SCHEMBL89321 | 0.88 | HTR1A (0.41) | HTR1ASLC6A4PARP1RENCYP2D6 | |
| SCHEMBL31544850 | 0.88 | MAOB (0.33) | HTR1ASLC6A4CXCR3 | |
| SCHEMBL89104 | 0.85 | REN (0.42) | HTR1ASLC6A4PTGS2RENCXCR3 | |
| SCHEMBL31545418 | 0.83 | ALDH1A1 (0.42) | HTR1ASLC6A4PARP1REN | |
| SCHEMBL89741 | 0.82 | ALDH1A1 (0.41) | HTR1ASLC6A4PARP1CYP2D6 | |
| SCHEMBL89264 | 0.82 | REN (0.38) | HTR1ASLC6A4PARP1RENCXCR3 | |
| SCHEMBL8235663 | 0.82 | REN (0.36) | HTR1ASLC6A4PARP1RENCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | HTR1A 652/4885SLC6A4 895/4885PARP1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.